BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 25339396)

  • 1. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.
    Schiffman M; Burk RD; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Aldrich C; Tam T; Erlich H; Apple R; Befano B; Castle PE
    J Clin Microbiol; 2015 Jan; 53(1):52-9. PubMed ID: 25339396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
    J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
    Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
    BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
    Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
    Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 9. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.
    Castle PE; Shaber R; LaMere BJ; Kinney W; Fetterma B; Poitras N; Lorey T; Schiffman M; Dunne A; Ostolaza JM; McKinney S; Burk RD
    Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):946-53. PubMed ID: 21415357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland.
    Leinonen MK; Anttila A; Malila N; Dillner J; Forslund O; Nieminen P
    Br J Cancer; 2013 Nov; 109(11):2941-50. PubMed ID: 24136148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China.
    Dun C; Yuan M; Zhao X; Hu S; Arbyn M; Zhao F
    Cancer Med; 2024 Jun; 13(11):e7316. PubMed ID: 38828559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
    Stoler MH; Parvu V; Yanson K; Andrews J; Vaughan L
    Gynecol Oncol; 2023 Jul; 174():68-75. PubMed ID: 37149907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities.
    Gage JC; Schiffman M; Solomon D; Wheeler CM; Gravitt PE; Castle PE; Wentzensen N
    Cancer Epidemiol Biomarkers Prev; 2013 Jun; 22(6):1095-101. PubMed ID: 23603204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
    Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
    Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the effectiveness of HPV16/18 infection referred for colposcopy in cervical cancer screening in Northwest of China.
    Zhang Q; Zhao M; Cao D; Wei X; Wang L; Li Y; Yang T; Zhao J; Pei M; Jia H; Cao S; Quan S; Yang X
    J Med Virol; 2018 Jan; 90(1):165-171. PubMed ID: 28710863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results.
    Schiffman M; Vaughan LM; Raine-Bennett TR; Castle PE; Katki HA; Gage JC; Fetterman B; Befano B; Wentzensen N
    Gynecol Oncol; 2015 Sep; 138(3):573-8. PubMed ID: 26148763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
    Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
    J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
    Song F; Du H; Wang C; Huang X; Wu R;
    PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.